En Es

Industry News

Hong Kong Hospital to Acquire Accuray Radixact Systems

By HospiMedica International staff writers
04 Jan 2017

Image: The Radixact system (Photo courtesy of Accuray).Accuray Incorporated (Sunnyvale, CA, USA) has signed an agreement with Hong Kong Sanatorium & Hospital [HKSH] (Happy Valley, Hong Kong) for the acquisition of three Radixact systems to provide clinicians and their patients’ access to advanced radiation therapy.

Out of the three Radixact systems, two will replace the existing TomoTherapy systems, while one will be installed in a new bunker. As per the agreement, HKSH's existing CyberKnife M6 system will also be upgraded with the latest features for motion management and treatment efficiency. With this, HKSH will become the first hospital in Asia to have both the Radixact and CyberKnife M6 systems for treating patients.

Following the agreement with Accuray, HKSH will now be able to treat the full range of cancer patients by using the Radixact system, considered to be the next-generation helical radiation therapy technology. Accuray’s Radixact systems will allow HKSH to deliver precise radiation treatments and adjust the therapy according to changes in tumor size, shape and location, as well as subtle changes in the location of organs and other healthy tissue.

"HKSH has a well-earned reputation for high-quality patient care based on advanced knowledge, expertise and technology. We are honored to expand Accuray's role in helping their team meet the needs of their rapidly growing patient population. HKSH will be the first hospital in Asia to have both the Radixact and CyberKnife M6 Systems available for patient treatments. This commitment shows confidence in our new Radixact System and in the Accuray team's ability to help the Hospital provide 'Quality in Service; Excellence in Care,'" said Josh Levine, President and CEO of Accuray.

"We are excited to build on the previous experience we have had with the TomoTherapy platform by moving to the next generation helical platform from Accuray. The TomoTherapy platform has enabled us to treat a wide range of cancer patients. The CyberKnife M6 and Radixact Systems, together, are complementary technologies that will enable us to offer each cancer patient the advanced radiation therapy best suited to precisely treating their disease while minimizing side effects," said Mr. Wyman Li, Administration Manager of HKSH.

"Hong Kong Sanatorium & Hospital has had great success in the treatment of cancer, the number one cause of death in Hong Kong. We are excited to build on our initial work with Accuray to offer state-of-the-art advanced radiation treatments to patients. The Radixact and CyberKnife M6 Systems' unique modalities and precision will enable us to meet growing demand for high quality treatment and will play a key role in the armamentarium of state-of-the art technologies that form the backbone of the Hospital's arsenal against cancer," he added.

Related Links:
Hong Kong Sanatorium & Hospital

E-mail Print
FaceBook Twitter Google+ Linked in


Accuray is a radiation oncology company that develops, manufactures and sells tumor treatment solutions. Its solutions are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy.
More info

Additional news

27 Jun 2022
Robot-Assisted Surgical Devices Market Driven by Increased Demand for Patient-Specific Surgeries
Given the growing incidence of lifestyle diseases and demand for affordable healthcare, effective surgery using robotic devices can result in a decline in treatment costs and drive the growth of the global robot-assisted surgical devices (RASD) market.
Read More
24 Jun 2022
Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests
Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction of customary closing conditions.
Read More
23 Jun 2022
Hospital Microbiology Testing Market Driven by Increasing Prevalence of Chronic Diseases
Rising medical expenditure as well as the presence of well-established modern healthcare infrastructure in various developed as well as developing regions is fueling the growth of the global hospital microbiology testing market.
Read More
22 Jun 2022
Global Minimally Invasive Surgery (MIS) Market to Surpass USD 325 Billion by 2031
The global MIS market is projected to surpass USD 325 billion by 2031, driven by growing patient awareness of the advantages of MIS over open surgeries, continuous innovation in surgical robots, and constant advancements in other MIS-associated technologies during the 2022-2031 forecast period.
Read More
21 Jun 2022
Medix Biochemica Acquires IVD Raw Materials Producer Bioresource Technology
Medix Biochemica (Espoo, Finland) has acquired 100% of the shares of Bioresource Technology (BRT, Weston, FL, USA) to broaden its base matrix capabilities and further strengthen its local presence in the US market.
Read More
21 Jun 2022
Global Bedside Testing Market to Witness Promising Prospects in Critical Care
Point-of-care or point-of-use diagnostics, also known as bedside testing, has gained increased prominence in analytical testing over the past few years as it provides clinically relevant information without the need for a dedicated laboratory.
Read More
20 Jun 2022
Global Sepsis Diagnostics Market Driven by Rising Hospital-Acquired Illnesses
The global sepsis diagnostics market is expected to grow at a CAGR of 8.3% during the period 2022-2028 to reach almost USD 0.88 billion by 2028, driven by a rise in the number of hospital-acquired illnesses and the rapidly growing molecular diagnostics market, although the high cost of automated diagnostic instruments could hamper market growth.
Read More
14 Jun 2022
BD Partners with Mayo Clinic Platform for Access to World's Largest Collection of Clinical Data
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has entered into a collaboration with Mayo Clinic Platform (Rochester, MN, USA) to access de-identified patient data from Mayo Clinic Platform_Discover.
Read More
14 Jun 2022
Quidel Partners with Global Lyme Alliance, Leads in Lyme Disease Testing
Quidel Corporation (San Diego, CA, USA) is joining forces with Global Lyme Alliance (Stamford, CT, USA) to heighten public awareness around Lyme disease during Lyme Disease Awareness Month (in May) and beyond.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions